CDH2 and neoplasm: Coordinated lost and gain of different epithelial (β-catenin, E-cadherin) and mesenchymal (vimentin, N-cadherin, fibronectin, and α-smooth muscle actin) markers, respectively, enhanced migratory and invasive abilities, increased apoptosis resistance, and extended production of extracellular matrix elements have been shown in human tumor samples and have been correlated to metastatic progression [9,10].